Researchers studied epidemiological, clinical, microbiological and laboratory data from patients with recurrent CDI due to relapse or reinfection over five years and compared them to a control group. Of 60 patients with recurrent CDI, 63.9 percent suffered from relapse and 36.1 percent from reinfection.
Researchers found previous antibiotic exposure was a risk factor for recurrent CDI. Patients suffering from relapse had previous antibiotic exposure more frequently than patients with reinfection.
They also found patients with reinfection suffered more frequently from chronic liver disease than relapse patients did.
Additionally, sporulation and germination frequency of the recurrent CDI group were higher than the control group.
More articles on healthcare quality:
Top 10 infection control stories, Sept. 18-22
6 children hospitalized in Wisconsin E coli outbreak
Flint’s Legionnaires’ outbreak likely killed more people than reported, says expert
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
